Oncolytics Biotech Inc.

10:30 AM - 10:45 AM (EDT), Wednesday, October 23, 2019 ・ 2nd Floor
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype - turning "cold" tumors "hot" - through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.
Ticker:
ONCY
Exchange:
NASDAQ
Company Type:
Company Website:
Company HQ State:
Alberta
Company HQ Country:
Canada
Year Founded:
1998
Main Therapeutic Focus:
Lead Product in Development:
Pelareorep
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1